ORY-1001靶向赖氨酸特异性去甲基化酶1下调胶质母细胞瘤Notch/HES1通路的表达并发挥抗肿瘤作用

ORY-1001 inhibits glioblastoma cell growth by downregulating the Notch/HES1 pathway via suppressing lysine-specific demethylase 1 expression

目的 探究赖氨酸特异性去甲基化酶1(LSD1)抑制剂ORY-1001对胶质母细胞瘤(GBM)的抑瘤作用和机制。方法 从公开数据库(TCGA和HPA)下载相关数据,分析LSD1在GBM和正常脑中的表达情况。将24只雌性BALB/c小鼠,随机分为对照组与ORY-1001组,12只/组。肿瘤细胞种植后,每7 d用400μg/kg ORY-1001进行灌胃,检测肿瘤生长和动物生存时间,评估ORY-1001对GBM的抗肿瘤效应。检测A490 nm值测定ORY-1001对GBM细胞活力的影响。Western blotting检测ORY-1001对LSD1表达的影响。利用慢病毒试剂,构建稳定敲降LSD1的GBM细胞(sh-LSD1),并通过动物成瘤实验评估沉默LSD1在活体动物内的作用以检测LSD1药物抑制获得的表型特异性。运用生物信息学方法分析与LSD1相关的基因及通路。Western blotting检测沉默LSD1及不同剂量ORY-1001治疗后Notch/HES1通路的表达。通过慢病毒转染,构建稳定过表达Notch1(oeNotch1)的U87细胞。测定过表达Notch1后,ORY-1001对GBM动物模型肿瘤生长及生存时间的影响。通过ChIP揭示ORY-1001对Notch/HES1通路的具体调控机制。结果 LSD1在GBM中高表达,并与患者的预后呈负相关(P<0.001)。ORY-1001治疗以及LSD1基因沉默都使荷瘤动物肿瘤负荷减轻(P<0.05)和生存时间延长(P<0.001),对多种GBM细胞的活力均表现出抑制作用(P<0.05)。ORY-1001呈剂量依赖性地抑制LSD1的表达。Notch通路富集了与LSD1抑制相关的差异基因,LSD1沉默及ORY-1001治疗后Notch/HES1通路表达显著下调(P<0.05),逆转了ORY-1001对GBM的抗肿瘤作用(P<0.05)。结论 ORY-1001通过抑制GBM中LSD1的表达而下调Notch/HES1通路,并发挥抗肿瘤效应。

Objective To explore the inhibitory effect ORY-1001,a lysine-specific histone demethylase 1(LSD1)inhibitor,on growth of glioblastoma(GBM)and the underlying mechanism.Methods We analyzed LSD1 expressions in GBM and normal brain tissues based on data from TCGA and HPA databases.Female BALB/c mouse models bearing xenografts derived from U87 cells or cells with lentivirus-mediated LSD1 silencing or Notch overexpression were treated with saline or 400µg/kg ORY-1001 by gavage every 7 days,and GBM formation and survival time of the mice were recorded.The effect of ORY-1001 on GBM cell viability was assessed,and its effect on LSD1 expression was analyzed with Western blotting.The genes and pathways associated with LSD1 were analyzed using bioinformatics methods.Western blotting and qRT-PCR were used to detect Notch/HES1 pathway expression after LSD1 silencing and ORY-1001 treatment.The impact of ORY-1001 on viability of U87 cells with Notch1 silencing or overexpression was assessed,and the regulatory effects of ORY-1001 on Notch/HES1 pathway were analyzed using chromatin immunoprecipitation assay.Results A high expression of LSD1 in GBM was negatively correlated with patient survival(P<0.001).ORY-1001 and LSD1 silencing obviously reduced tumor burden and prolonged the survival time of GBM-bearing mice.ORY-1001 treatment significantly inhibited the viability and dose�dependently decreased LSD1 expression in GBM cells,and such inhibitory effect of ORY-1001 was attenuated by LSD1 silencing.The Notch pathway enriched the differential genes related to LSD1,and Notch/HES1 pathway expression was significantly down-regulated after LSD1 silencing and ORY-1001 treatment.Notch1 overexpression significantly attenuated the anti-tumor effect of ORY-1001 on GBM.Mechanistically,ORY-1001 disrupted the interaction between LSD1 and the Notch pathway target genes including Notch3,HES1 and CR2.Conclusion ORY-1001 down-regulates the Notch/HES1 pathway by inhibiting LSD1 expression to suppress the growth of GBM in mice.